信迪利单抗联合盐酸安罗替尼用于晚期非小细胞肺癌疗效研究

目的探讨信迪利单抗联合盐酸安罗替尼用于晚期非小细胞肺癌疗效研究。方法回顾性选取2020年1月至2021年7月池州市人民医院收治晚期非小细胞肺癌患者56例作为研究对象,根据治疗方法不同将患者分为对照组(n=32)和观察组(n=24)。对照组采用信迪利单抗⁺化疗,观察组采用信迪利单抗⁺盐酸安罗替尼治疗。观察两组患者治疗前及治疗6周后相关血清免疫指标和肿瘤标志物水平,治疗6周后客观缓解率(OOR)和疾病控制率(DCR)及治疗期间不良反应发生情况。结果两组患者治疗6周后T细胞亚群CD4⁺、CD4⁺/CD8⁺水平较治疗前升高,CD8⁺较治疗前降低,且观察组治疗6周后CD4⁺、CD4⁺/CD8⁺水平为(37.98±3.58)%、1.63±0.28,高于对照组(34.97±3.34)%、1.38±0.24],CD8⁺水平为(27.38±2.67)%,低于对照组(30.77±1.16)%],差异均有统计学意义(P<0.05)。两组患者治疗6周后癌胚抗原、血清癌抗原125水平较治疗前降低,且观察组治疗6周后癌胚抗原、癌抗原125水平为(47.64±5.32)ng/mL、(61.57±10.45)U/mL,低于对照组(68.91±7.46)ng/mL、(94.58±12.13)U/mL],差异均有统计学意义(P<0.05)。观察组DCR为91.67%,高于对照组(62.50%),差异有统计学意义(P<0.05)。观察组与对照组ORR、总不良反应发生率比较(70.83%vs.50.00%,33.33%vs.37.50%)差异无统计学意义(P>0.05)。结论信迪利单抗联合盐酸安罗替尼用于晚期非小细胞肺癌能有效改善患者相关血清免疫指标及肿瘤标志物水平,提高疾病控制率。

Efficacy of sintilimab combined with anlotinib hydrochloride in advanced non-small cell lung cancer

Objective To investigate the efficacy of sintilimab combined with anlotinib hydrochloride in advanced non-small cell lung cancer(NSCLC).Methods Fifty-six patients with advanced NSCLC admitted to our hospital from January 2020 to July 2021 were analyzed and divided into control group(n=24)and observation group(n=32)according to different treatment methods.The levels of related serum immune indexes and tumor markers before chemotherapy and after 6 weeks of chemotherapy,the objective response rate(ORR)and disease control rate(DCR)after 6 weeks of treatment,and the occurrence of adverse reactions during treatment were observed.Results After 6 weeks of treatment,the levels of CD4⁺ and CD4⁺/CD8⁺ of T cell subsets in the two groups were higher than before treatment,while CD8⁺was lower than before treatment,After 6 weeks of treatment,the levels of CD4⁺ and CD4⁺/CD8⁺ in the observation group were(37.98±3.58)%,1.63±0.28,which were higher than those in the control group(34.97±3.34)%,1.38±0.24],and the level of CD8⁺was(27.38±2.67)%,lower than the control group(30.77±1.16)%],the difference was statistically significant(P<0.05).After 6 weeks of treatment,the levels of carcinoembryonic antigen and serum cancer antigen 125 in the two groups were lower than those before treatment,and the levels of carcinoembryonic antigen and cancer antigen 125 in the observation group after 6 weeks of treatment were(47.64±5.32)ng/mL,(61.57±10.45)U/mL,which were lower than those in the control group(68.91±7.46)ng/mL,(94.58±12.13)U/mL],the differences were statistically significant(P<0.05).The DCR of the observation group was 91.67%,which was higher than that of the control group(62.50%),and the difference was statistically significant(P<0.05).There was no significant difference in ORR and total adverse reactions between the observation group and the control group(70.83%vs.50.00%,33.33%vs.37.50%)(P>0.05).Conclusion Cintibumab combined with anlotinib hydrochloride for advanced NSCLC can effectively improve the serum immune indexes and tumor marker levels of patients,and improve their disease control rate.